Rabies: all 114 studies

Page 1 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• An Expanded Access Program for SYN023 in Rabies TreatmentAvailableNCT07706907
• A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)Enrolling by invitationNCT07500207Phase 3
• Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.Not yet recruitingNCT07455318Phase 3
• A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal AntibodyNot yet recruitingNCT07445815Phase 2
• Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies VaccineNot yet recruitingNCT07416110Phase 3
• Safety and Immunogenicity of ID vs IM Rabies VaccineNot yet recruitingNCT07345208Phase 2/3
• Real World Evidence Study of SYN023 in Children Exposed to RabiesRecruitingNCT07327307
• Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed VaccineNot yet recruitingNCT07168018Phase 2
• Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis RegimenNot yet recruitingNCT07055893Phase 3
• Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)Not yet recruitingNCT07055880Phase 2
• Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis RegimenNot yet recruitingNCT07055295Phase 3
• Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)Not yet recruitingNCT07028801Phase 3
• A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-driedRecruitingNCT07021703Phase 1
• Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical TrialsNot yet recruitingNCT06548139Phase 2
• Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)Not yet recruitingNCT05969626Phase 3
• A Phase III Clinical Study to Evaluate SYN023's Efficacy and SafetyCompletedNCT04644484Phase 3Results posted
• Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of AdultsCompletedNCT04127786Phase 3Results posted
• Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult SubjectsCompletedNCT04019444Phase 1Results posted
• Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in AdultsCompletedNCT03965962Phase 3Results posted
• Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of RabiesCompletedNCT03961555Phase 2Results posted
• A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy AdultsCompletedNCT03713086Phase 1Results posted
• Responses to Rabies Vaccine in Adults With or Without AntibioticsCompletedNCT03557008Phase 4Results posted
• Immunogenicity and Safety of a Purified Vero Rabies VaccineCompletedNCT03145766Phase 2Results posted
• A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies VaccinesCompletedNCT02956746Phase 1/2Results posted
• Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.CompletedNCT02564471Phase 4Results posted
• A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.CompletedNCT02545517Phase 3Results posted
• Immunogenicity of Rabies Vaccine for Pre Exposure ProphylaxisCompletedNCT02374814Phase 4Results posted
• Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of AgeCompletedNCT02177032Phase 3Results posted
• Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy SubjectsCompletedNCT02040090Phase 2/3Results posted
• A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older AdultsCompletedNCT01680016Phase 3Results posted
• Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult SubjectsCompletedNCT01662440Phase 3Results posted
• A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedNCT01466387Phase 3Results posted
• Simplifying the Rabies Pre-exposure VaccinationCompletedNCT01388985Phase 3Results posted
• Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure SchedulesCompletedNCT01365494Phase 4Results posted
• Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary VaccinationCompletedNCT01286493Not applicableResults posted
• Study of Intradermal Administration of PCEC Rabies VaccineCompletedNCT01044199Not applicableResults posted
• Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)CompletedNCT00825305Phase 3Results posted
• Real-World Effectiveness of Zamerovimab and Mazorelvimab and Vaccine for Rabies Grade III Exposure in NanyangActive, not recruitingNCT07624461
• Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-driedCompletedNCT07357545Phase 3
• SYN023 With Rabies Vaccine in Healthy Pediatric SubjectsCompletedNCT07342257Phase 1
• A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 YearsActive, not recruitingNCT07275645Phase 3
• Adherence to Anti-rabies Post-exposure Prophylactic ProtocolsCompletedNCT07012083
• A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy AdultsCompletedNCT06998004Phase 1
• Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and IntradermallyCompletedNCT06433440Phase 4
• To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)CompletedNCT06177249Phase 3
• A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 YearsCompletedNCT06132789Phase 1
• A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)CompletedNCT06078423Phase 3
• The Role of Fatty Acids in Vaccine EfficacyCompletedNCT05987384Not applicable
• Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and IntradermallyCompletedNCT05937113Phase 4
• Study to Evaluate GR1801's Efficacy and SafetyCompletedNCT05846568Phase 3
• Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1Status unknownNCT05832073Early Phase 1
• Social Media as an Information, Education and Communication Tool for Rabies Prevention: An Interventional StudyCompletedNCT05702008Not applicable
• Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in CambodiaCompletedNCT05684185
• A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-driedActive, not recruitingNCT05667974Phase 3
• Vaccine Prevention of Rabies Adopts 4-shot Immunization MethodCompletedNCT05549908Phase 3
• Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies VaccineCompletedNCT05547815Phase 4
• Prevention of Rabies With Four Doses of Rabies VaccineCompletedNCT05545371Phase 3
• Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies VaccineStatus unknownNCT05453487Phase 4
• Survey of Human Rabies Immune Globulin Safety in ChildrenTerminatedNCT05382650
• Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis ProjectCompletedNCT05350735Not applicable
• A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)Active, not recruitingNCT04852068Phase 3
• Immunity Persistence After Abridged Intradermal Rabies PEPCompletedNCT04829630Not applicable
• Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in ThaïlandCompletedNCT04594551Phase 3
• Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in ThaïlandCompletedNCT04478084Phase 3
• A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabGActive, not recruitingNCT04270838Phase 1/2
• Rabies Treatment by Exposure of Patient to X-RayStatus unknownNCT04261322Early Phase 1
• Improving Adherence to Rabies PEP Guideline RecommendationsCompletedNCT04213950Not applicable
• Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabGTerminatedNCT04162600Phase 1
• A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy AdultsCompletedNCT04062669Phase 1
• Immunity Duration of Rabies Vaccine and Booster Dose Effects at 10 Years Post-primary VaccinationCompletedNCT03774628Not applicable
• Safety of Rabivax-S for Pre-exposure ProphylaxisCompletedNCT03741270Phase 4
• Immunological Tolerance After Frequent Rabies Booster VaccinationsStatus unknownNCT03729102Not applicable
• Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One YearCompletedNCT03700242Phase 3
• Integrating Community Interventions to Eliminate Neglected Tropical DiseasesCompletedNCT03667079Not applicable
• Non-specific Effects of Rabies VaccineCompletedNCT03656198Phase 4
• Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune ResponseStatus unknownNCT03524417Not applicable
• Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected AdultsStatus unknownNCT03228069Not applicable
• A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese ChildrenWithdrawnNCT03192371Phase 4
• Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese PatientsCompletedNCT03093545Not applicable
• Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated RegimenCompletedNCT02956421Phase 2
• Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to RabiesCompletedNCT02912845Phase 3
• Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered IntramuscularlyCompletedNCT02729168Not applicable
• Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA AdjuvantCompletedNCT02657161Phase 1
• Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.CompletedNCT02559921Phase 2
• Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected AdultsStatus unknownNCT02547727Not applicable
• A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese SubjectsCompletedNCT02491541Phase 3
• Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in ChildrenStatus unknownNCT02339896
• The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese HumansCompletedNCT02281396Phase 1
• One-visit Multi-site Intradermal Rabies Vaccination - Dose FindingStatus unknownNCT02276625Phase 2
• RNActive® Rabies Vaccine (CV7201) in Healthy AdultsCompletedNCT02241135Phase 1
• Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy AdultsCompletedNCT02238756Phase 1
• An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)CompletedNCT02139657Phase 1
• Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis RegimenCompletedNCT01930357Phase 2
• Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure RegimenCompletedNCT01877395Phase 2
• The Protection Effect of Speeda® Rabies Vaccine for Human UseCompletedNCT01827917Phase 4
• The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human UseCompletedNCT01821911Phase 4
• Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure UseCompletedNCT01784874Phase 2
• Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies ImmunoglobulinsCompletedNCT01641315Not applicable
• Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis RegimenCompletedNCT01622062Phase 3
• Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune ResponseCompletedNCT01610362Not applicable

← Rabies overview